Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Calgary

$17,500.00

A high throughput RNAi screen in paediatric rhabdomyosarcoma to identify tumour specific inhibitors of cytotoxic T cell activity

FY 2016-17

Summary
Childhood cancers represent the leading cause of disease-related death amongst children. Despite major advances in cancer therapy, conventional treatments for childhood cancers often harm multiple organs and may cause health problems for cancer survivors months or even years after treatment has ended. For this reason, our lab believes in treating paediatric cancers with a less toxic, more effective form of cancer therapy known as immunotherapy.Most patients' immune systems have the potential to combat cancer. However, tumour cells can employ strategies to evade the immune system, often by expressing inhibitory molecules that disguise them from cancer fighting T cells. Some forms of immunotherapy – called checkpoint blockade – work by blocking these molecules, allowing T cells in the tumour to recognize and fight the patient's cancer. Unfortunately, many of these treatments also disrupt inhibitory molecules expressed by normal cells within the body. This allows T cells to attack healthy tissue, causing systemic immune-related adverse effects. In order to alleviate negative side effects associated with current checkpoint blockade strategies, we propose carrying out a robotized screen to identify inhibitory molecules expressed specifically by paediatric cancer cells that mask them from the immune system. In doing so, we hope to identify target molecules for cancer immunotherapy that can enhance anti-tumour immune activity while avoiding systemic toxicities.
Program
Master's Award: Canada Graduate Scholarships
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
367302
Name
Rajwani Jahanara
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
A high throughput RNAi screen in paediatric rhabdomyosarcoma to identify tumour specific inhibitors of cytotoxic T cell activity
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Immunotherapy; Checkpoint Blockade; High-Throughput Screen; Immunology; Pediatric Sarcomas; Small Molecule Inhibitors
Abstract
Childhood cancers represent the leading cause of disease-related death amongst children. Despite major advances in cancer therapy, conventional treatments for childhood cancers often harm multiple organs and may cause health problems for cancer survivors months or even years after treatment has ended. For this reason, our lab believes in treating paediatric cancers with a less toxic, more effective form of cancer therapy known as immunotherapy.Most patients' immune systems have the potential to combat cancer. However, tumour cells can employ strategies to evade the immune system, often by expressing inhibitory molecules that disguise them from cancer fighting T cells. Some forms of immunotherapy – called checkpoint blockade – work by blocking these molecules, allowing T cells in the tumour to recognize and fight the patient's cancer. Unfortunately, many of these treatments also disrupt inhibitory molecules expressed by normal cells within the body. This allows T cells to attack healthy tissue, causing systemic immune-related adverse effects. In order to alleviate negative side effects associated with current checkpoint blockade strategies, we propose carrying out a robotized screen to identify inhibitory molecules expressed specifically by paediatric cancer cells that mask them from the immune system. In doing so, we hope to identify target molecules for cancer immunotherapy that can enhance anti-tumour immune activity while avoiding systemic toxicities.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rajwani, Jahanara
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~